{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:26:13Z","timestamp":1764602773244},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"960","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Psychosis is common in Parkinson\u2019s disease (PD), particularly in its later stages. The symptoms range from comparatively minor illusions, vivid dreams, and occasional, non-disturbing visual hallucinations to frank psychosis. The pathogenesis of psychosis in PD is not fully known. Management of psychosis in PD requires a multidisciplinary approach. Some of the newer atypical antipsychotics are effective against psychosis with no significant worsening of PD. Psychosis in PD is associated with poor quality of life for patients and the carers.<\/jats:p>","DOI":"10.1136\/pgmj.2004.032029","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T18:02:58Z","timestamp":1128621778000},"page":"644-646","source":"Crossref","is-referenced-by-count":40,"title":["Psychosis in Parkinson\u2019s disease"],"prefix":"10.1093","volume":"81","author":[{"given":"B R","family":"Thanvi","sequence":"first","affiliation":[{"name":"Department of Medicine for Older People, Leicester General Hospital, University Hospitals of Leicester NHS Trust , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T C N","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Medicine for Older People, Leicester General Hospital, University Hospitals of Leicester NHS Trust , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D P","family":"Harsh","sequence":"additional","affiliation":[{"name":"Hellesdon Hospital , Norwich , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,10,6]]},"reference":[{"key":"2023042408415357800_R1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1532-5415.1996.tb00918.x","article-title":"Psychotic symptoms in Parkinson\u2019s disease patients with dementia.","volume":"44","author":"Naimark","year":"1996","journal-title":"J Am Geriatr Soc"},{"key":"2023042408415357800_R2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson\u2019s disease.","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"2023042408415357800_R3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/jnnp.63.4.434","article-title":"Hallucinations in idiopathic Parkinson\u2019s disease.","volume":"63","author":"Graham","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023042408415357800_R4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","article-title":"Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey.","volume":"70","author":"Barnes","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023042408415357800_R5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","article-title":"Visual hallucinations associated with Parkinson\u2019s disease.","volume":"53","author":"Sanchez-Ramos","year":"1996","journal-title":"Arch Neurol"},{"key":"2023042408415357800_R6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-004-0209-9","article-title":"Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson\u2019s disease.","volume":"111","author":"Merims","year":"2004","journal-title":"J Neural Transm"},{"key":"2023042408415357800_R7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/pmj.79.936.561","article-title":"Neuropsychiatric non-motor aspects of Parkinson\u2019s disease.","volume":"79","author":"Thanvi","year":"2003","journal-title":"Postgrad Med J"},{"key":"2023042408415357800_R8","first-page":"124","article-title":"In Parkinson\u2019s disease in the older patient. In: Playfer JR, Hindle JV, eds.","author":"Hindle","year":"2001","journal-title":"Neuropsychiatry"},{"key":"2023042408415357800_R9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01663632","article-title":"Responsibility of extrastriatal areas for the appearance of psychotic symptoms.","volume":"37","author":"Birkmayer","year":"1975","journal-title":"J Neural Transm"},{"key":"2023042408415357800_R10","first-page":"393","article-title":"Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meyernert in Parkinson\u2019s disease and Alzheimer\u2019s disease.","volume":"45","author":"Whitehouse","year":"1986","journal-title":"Adv Neurol"},{"key":"2023042408415357800_R11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/ajp.139.4.494","article-title":"Pharmacology of hallucinations induced by long-term drug therapy.","volume":"139","author":"Goetz","year":"1982","journal-title":"Am J Psychiatry"},{"key":"2023042408415357800_R12","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S1353-8020(03)00022-1","article-title":"Neuropsychological and perceptual defects in Parkinson\u2019s disease.","volume":"9","author":"Bodis-Wollner","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"2023042408415357800_R13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0028-3932(02)00182-3","article-title":"Reality monitoring and visual hallucinations in Parkinson\u2019s disease.","volume":"41","author":"Barnes","year":"2003","journal-title":"Neuropsychologia"},{"key":"2023042408415357800_R14","volume-title":"Hallucinations and parkinsonism. Seventeenth annual symposia on etiology, pathogenesis, and treatment of Parkinson\u2019s disease and other movement disorders, Parkinson Study Group","author":"Goetz","year":"2003"},{"key":"2023042408415357800_R15","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.63.8_suppl_3.S28","article-title":"Hallucinations and sleep disturbances in Parkinson\u2019s disease.","volume":"63","author":"Kulisevsky","year":"2004","journal-title":"Neurology"},{"key":"2023042408415357800_R16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson\u2019s disease and psychosis.","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"key":"2023042408415357800_R17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/jnnp.65.5.774","article-title":"Olanzapine in the treatment of hallucinosis in idiopathic Parkinson\u2019s disease: a cautionary note.","volume":"65","author":"Graham","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023042408415357800_R18","volume-title":"Latest news. 9 Mar 2004. Atypical antipsychotic drugs and stroke","author":"Committee on Safety of Medicines"},{"key":"2023042408415357800_R19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"2023042408415357800_R20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience.","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"2023042408415357800_R21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mds.20260","article-title":"Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson\u2019s disease.","volume":"20","author":"Fernandez","year":"2005","journal-title":"Mov Disord"},{"key":"2023042408415357800_R22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","article-title":"Longitudinal outcome of Parkinson\u2019s disease patients with psychosis.","volume":"60","author":"Factor","year":"2003","journal-title":"Neurology"},{"key":"2023042408415357800_R23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up.","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023042408415357800_R24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0891988704267457","article-title":"Psychosis in Parkinson\u2019s disease.","volume":"17","author":"Wint","year":"2004","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"2023042408415357800_R25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","article-title":"Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson\u2019s disease: a case series.","volume":"18","author":"Bullock","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"2023042408415357800_R26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease.","volume":"25","author":"Bergman","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"2023042408415357800_R27","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist.","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"},{"key":"2023042408415357800_R28","first-page":"202","article-title":"Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson\u2019s disease.","volume":"65","author":"Hoflich","year":"1994","journal-title":"Nervenarzt"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/81\/960\/644\/50025645\/postgradmedj-81-644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/81\/960\/644\/50025645\/postgradmedj-81-644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:51:47Z","timestamp":1682326307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/81\/960\/644\/7059782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":28,"journal-issue":{"issue":"960","published-online":{"date-parts":[[2005,10,6]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2004.032029","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,10,1]]}}}